State Street Corp Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

State Street Corp reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 59,188,160 shares of the biopharmaceutical company’s stock after selling 335,515 shares during the quarter. State Street Corp’s holdings in Gilead Sciences were worth $6,562,191,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of GILD. Rothschild Investment LLC lifted its position in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares in the last quarter. Archer Investment Corp increased its stake in Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 87 shares during the last quarter. EPG Wealth Management LLC lifted its position in shares of Gilead Sciences by 2.0% during the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 89 shares in the last quarter. Southland Equity Partners LLC boosted its stake in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 92 shares during the last quarter. Finally, Putney Financial Group LLC grew its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $121.19 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $150.36 billion, a PE ratio of 18.79, a P/E/G ratio of 0.67 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a 50-day moving average price of $121.11 and a two-hundred day moving average price of $115.44.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price target on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. Finally, Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $130.65.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 135,757 shares of company stock valued at $16,616,127. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.